

EXHIBIT 15

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
CLARKSBURG DIVISION

REGENERON PHARMACEUTICALS, INC.,

Plaintiff,

v.

MYLAN PHARMACEUTICALS INC.,

Defendant.

Case No. 1:22-cv-00061-TSK

**CONFIDENTIAL – SUBJECT TO
PROTECTIVE ORDER**

**REGENERON PHARMACEUTICALS, INC.’S OBJECTIONS AND RESPONSES TO
DEFENDANT’S FIRST SET OF INTERROGATORIES (NOS. 1–17)**

Pursuant to Rules 33 of the Federal Rules of Civil Procedure and Rule 33.01 of the Local Rules of Civil Procedure, Plaintiff Regeneron Pharmaceuticals, Inc. (“Plaintiff” and/or “Regeneron”), by and through its counsel, hereby submits the following objections and responses to Defendant Mylan Pharmaceuticals Inc.’s (“Defendant” and/or “Mylan”) First Set of Interrogatories (Nos. 1–17) (“Interrogatories”).

These objections and responses are based on information currently available and without prejudice to Regeneron’s right to produce evidence of any subsequently discovered fact or information, to add, modify, or otherwise change, amend, or supplement its responses as appropriate or to correct any inadvertent errors, mistakes, or omissions.

GENERAL OBJECTIONS

1. Regeneron incorporates by reference these General Objections into each and every specific response below. A specific response may repeat a General Objection for emphasis or for other reasons. The omission of any General Objection in any specific response to an Interrogatory is not intended to be and should not be construed as a waiver or limitation of any

first publicly used upon the launch of Eylea following the first FDA approval on November 18, 2011.

With respect to U.S. Patent No. 11,104,715, **Regeneron Protected Material**

Regeneron Protected Material The first publication of the patent family specification occurred when U.S. 2021/0171570 was published on June 10, 2021.

INTERROGATORY NO. 6

If Regeneron contends that any reference identified as prior art in Mylan's Detailed Statements provided pursuant to 42 U.S.C. § 262(l)(3)(B) and/or § 262(l)(7)(B) does not qualify as prior art under 35 U.S.C. § 102 or 35 U.S.C. § 103 with respect to any asserted claim of the Initial Patents, based on the date and/or public availability of such reference (or any other reason), identify each such reference for each such claim and provide each basis for Regeneron's contention.

RESPONSE TO INTERROGATORY NO. 6:

Regeneron incorporates each of its General Objections as if fully set forth herein.

Regeneron objects to this Interrogatory to the extent that it seeks documents and things protected by the attorney-client privilege, the work-product doctrine, the common-interest privilege, or any other applicable privilege.

Subject to the foregoing general and specific objections, Regeneron states as follows:

With respect to U.S. Patent No. 11,084,865:

- U.S. Patent No. 7,608,261 is not prior art under either 35 U.S.C. § 102 or 35 U.S.C. § 103.
- U.S. Patent No. 8,110,546 is not prior art under either 35 U.S.C. § 102 or 35 U.S.C. § 103.
- U.S. Patent No. 8,647,842 is not prior art under either 35 U.S.C. § 102 or 35 U.S.C. § 103.
- U.S. Patent No. 9,340,594 is not prior art under either 35 U.S.C. § 102 or 35 U.S.C. § 103.

U.S.C. § 103.

- U.S. Patent No. 9,580,489 is not prior art under either 35 U.S.C. § 102 or 35 U.S.C. § 103.
- U.S. Patent No. 9,914,763 is not prior art under either 35 U.S.C. § 102 or 35 U.S.C. § 103.
- U.S. Patent No. 10,406,226 is not prior art under either 35 U.S.C. § 102 or 35 U.S.C. § 103.
- U.S. Patent No. 10,464,992 is not prior art under either 35 U.S.C. § 102 or 35 U.S.C. § 103.
- The '959 patent Petition for Patent Term Extension is not prior art under either 35 U.S.C. § 102 or 35 U.S.C. § 103.
- U.S. Patent No. 9,340,594 is not prior art under either 35 U.S.C. § 102 or 35 U.S.C. § 103.
- The 11/22/11 Response to 7/13/11 Office Action regarding U.S. Patent No. 8,110,546 is not prior art under either 35 U.S.C. § 102 or 35 U.S.C. § 103.
- U.S. Patent Application Publication No. 2016/0144025 is not prior art under either 35 U.S.C. § 102 or 35 U.S.C. § 103.
- The LUCENTIS® Prescribing Information (2006) is not prior art under 35 U.S.C. § 102 or 35 U.S.C. § 103.
- The EYLEA Prescribing Information (2011) is not prior art under 35 U.S.C. § 102 or 35 U.S.C. § 103.

With respect to the Yancopoulos Patents:

- The '959 patent Petition for Patent Term Extension is not prior art under either 35